Latest Breaking News On - ஒப்பந்த வணிகரீதியானது ஆர்கநைஸேஶந் - Page 1 : comparemela.com
In-Person and Remote Detailing Data from AnswerSuite Indicates Hybrid Model is Here to Stay
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
Syneos Health Acquires StudyKIK
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Syneos Health Leaders Recognized For Visionary Healthcare Expertise Through HBA
Healthcare Businesswomen’s Association Shines a Light on Lynn Hamilton and Katya Magonova
May 06, 2021 07:30 ET | Source: Syneos Health, Inc. Syneos Health, Inc.
MORRISVILLE, N.C., May 06, 2021 (GLOBE NEWSWIRE) Syneos Health
® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Lynn Hamilton, Senior Director, Clinical Operations and Clinical Development Services, and Katya Magonova, MBA, Senior Engagement Manager, Commercial Advisory Group, have been recognized by the Healthcare Businesswomen’s Association (HBA) as exemplary female leaders in the biopharmaceutical industry for 2021.
“While it was a tough decision to choose amongst a long list of women leaders across the organization, Lynn and Katya stood out. Both of these women are strong leaders, with exceptional talents, who continue to serve as role mode
Message :
Required fields
MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation (the “Selling Stockholders”) of an aggregate of 7,000,000 shares of the Company’s common stock (the “Offering”) pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission (“SEC”). The Selling Stockholders intend to grant the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock. Syneos Health is not selling any shares and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the Offering.
Illingworth Research Group Recognized with Queen’s Award for Enterprise: International Trade 2021
MORRISVILLE, N.C., April 30, 2021 (GLOBE NEWSWIRE) The Illingworth Research Group, a Syneos Health
® company, has been recognized with a 2021 Queen’s Award for Enterprise for International Trade. Illingworth Research Group™ is a leading global provider of clinical research home health services. With healthcare already becoming more local, COVID-19 has accelerated the need for in-home clinical trial services which have realized increasing demand in recent years.
Illingworth is one of only 205 UK-based organizations to be recognized with the prestigious Queen’s Award. With this acknowledgement, Illingworth Research becomes the first organization to be awarded the highly acclaimed industry SCRIP Award as Best Specialist Provider, and a Queens Award for Enterprise: International Trade, in the same year.
vimarsana © 2020. All Rights Reserved.